FDA Approves Study of New Treatment for Migraine

[Guest guest]

You have permission to publish this article electronically

or in print, free of charge, as long as the bylines are

included. A courtesy copy of your publication would be

appreciated - send to altfeder@....

Title: FDA Approves Study of New Treatment for Migraine

Word Count: 410

Author: Altfeder

Email: altfeder@...

Article URL:

http://www.submityourarticle.com/articles/easypublish.php?art_id=3612

The article is preformatted to 60CPL.

FDA Approves Study of New Treatment for Migraine

Copyright 2005 DeepDiscountPharmacy.net

The US Food and Drug Administration (FDA) has approved a

study in humans of a new treatment for migraine headache.

The treatment involves the precise delivery of tiny

electrical shocks to the occipital nerve in the back of the

neck to mask the perception of pain.

The study, known as PRISM (Precision Implantable Stimulator

for Migraine) will use Boston Scientific Corporation’s

(NYSE: BSX) Precision Neurostimulator to evaluate the

safety and effectiveness of occipital nerve stimulation to

treat migraine headache. The study will involve

approximately 150 patients at up to 15 sites in the United

States.

The treatment offers hope to the millions of migraine

sufferers who do not respond to conventional treatment. In

the U.S., there are more than 28 millions migraine

sufferers. Of these, up to 10 percent may not respond to

existing treatments. Existing treatments include a range of

medications and therapy.

" Occipital nerve stimulation has the potential to provide

relief to the large population of refractory migraine

sufferers who currently have no other medical treatments

available to them, " said Dr. Biondi, Director of the

Headache Management Program at Spaulding Rehabilitation

Hospital in Boston and Instructor of Neurology at Harvard

Medical School. " If effective, the Precision implantable

neurostimulator would provide a new treatment option to

free these patients from their long-standing headache pain. "

The Precision neurostimulator is the smallest rechargeable

neurostimulator on the market today and is already approved

by the FDA for spinal cord stimulation to treat chronic

pain. The device deliver precisely controlled electrical

impulses to the spinal cord which mask the perception of

pain. This treatment is prescribed for patients with

chronic pain in the limbs, trunk and back. In the new

study, the device will be used to stimulate the occipital

nerves located just under the skin at the back of the neck.

" As the smallest rechargeable neurostimulator available,

our Precision device represents a best-in-class

neuromodulation technology that has treated more than 2,000

patients suffering from chronic pain, " said H.

Greiner, President of Boston Scientific's Neuromodulation

Group. " We are excited about the prospect of extending

this same advanced technology to address the unmet needs of

migraine sufferers. "

Boston Scientific is a worldwide developer, manufacturer

and marketer of medical devices whose products are used in

a broad range of interventional medical specialties.

Boston Scientific's Neuromodulation Group is a global

leader in the development of implantable, high-technology

neurostimulation devices that include new treatments for

deafness and chronic pain.

About the Author:

Hayden is the owner of http://www.buybutalbital.net ,

http://www.onlinepharmacyzone.com and

http://www.buyfioricet.biz . He has written a series of

articles on medicine, pharmacology and the pharmacy

industry.